Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of KAE609 in adults with uncomplicated Plasmodium falciparum malaria
PACTR201801002894101Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of cipargamin in Malaria (10 arms), sponsored by Novartis. Primary endpoint: Primary safety endpoint. Started Nov 2017; status: recruiting.
02
Drugs
cipargamin
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR201801002894101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201801002894101.